Intervention: Pazopanib
Trial phase: Phase 3
ATC code: L01EX03 | L01XE11
SMILES: Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 477
Group description: Pazopanib
Eligibility criteria:
Inclusion Criteria:

written informed consent
At least 18 years old.
Histologically confirmed, FIGO stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma that was treated with surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy.
Study randomization at least 3 weeks and not more than 12 weeks from the date of the last chemotherapy dose, and all major toxicities from the previous chemotherapy must have resolved.
No evidence of disease progression
ECOG status of 0 or 2
Able to swallow and retain oral medication.
Adequate hematologic, hepatic, and renal system function as follows:

Hematologic

Absolute neutrophil count (ANC) at least 1.5 X 10^9/L
Hemoglobin at least 9 g/dL (or 5.59 mmol/L)
Platelets at least 100 X 10^9/L
Prothrombin time (PT) or international normalized ratio (INR) up to 1.2 X ULN
Activated partial thromboplastin time (aPTT) up to 1.2 X ULN Hepatic
Total bilirubin up to 1.5 X ULN
AST and ALT up to 2.5 X ULN Renal
Serum creatinine up to 1.5 mg/dL

Or, if greater than 1.5 mg/dL:

Calculated creatinine clearance at least 50 mL/min Urine Protein

Urine protein is 0, trace, or +1 determined by dipstick urinalysis, or < 1.0 gram determined by 24- hour urine protein analysis.
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception.

Exclusion Criteria:

Either (a) bulky disease, or (b) any residual disease which in the opinion of the investigator will need imminent second-line therapy
Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.
Clinically significant gastrointestinal abnormalities
Prolongation of corrected QT interval (QTc) > 480 msecs
History of any one or more cardiovascular conditions within the past 6 months prior to randomization
Cardiac angioplasty or stenting
Myocardial infarction
Unstable angina

Symptomatic peripheral vascular disease

Class III or IV congestive heart failure
Poorly controlled hypertension
History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months prior to randomization
Major surgery (including interval debulking) or trauma within 28 days, or minor surgical procedures within 7 days, prior to randomization, or has any non-healing wound, fracture, or ulcer.
Evidence of active bleeding or bleeding diathesis.
Hemoptysis within 6 weeks prior to randomization.
Endobronchial metastases.
Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
Investigational or anti-VEGF anticancer therapy prior to study randomization.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
Invasive malignancies that showed activity of disease within 5 years prior to randomization